The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.
采用异常不自主运动量表(AIMS)和简明精神病评定量表(BPRS)及副反应量表(TESS)在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。
Brief psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale (PANSS) were used to assess the effects.
采用简明精神病量表(BPRS)、阳性和阴性症状量表(PANSS)进行评价。
Therapeutic efficacy was measured by BPRS and the adverse reaction was rated by TESS. Steady serum level was monitored within 1, 2, 4, 6 week.
疗效和不良反应分别用简明精神病评定量表(BPRS)和副反应量表(TESS)进行评定,并测定治疗第1,2,4,6周的稳态血药浓度。
应用推荐